Novartis AG Sponsored ADR (NOTA)
Summary
NOTA Chart
Major Novartis shareholder calls for board shake-up after drug trial setbacks
A major shareholder in Novartis has called for a shake-up of the Swiss drugmaker's board to improve corporate governance after its shares suffered a record fall this week following back-to-back trial setbacks.
Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall
NVS' del-desiran fails the HARBOR study's primary endpoint, adding to recent pipeline setbacks as investors await next steps.
Dyne Therapeutics Remains A Buy Even As Novartis Trial Failure Hits DM1 Class
Dyne Therapeutics remains a Buy despite a 16% selloff triggered by Novartis' DM1 trial failure, which heightened platform-wide clinical risk perceptions. The Novartis HARBOR trial failure challenges the core RNA-targeting therapeutic thesis, raising doubts about translating biomarker gains into functional benefit for DYN's DM1 and DMD programs. DYN's lead asset, z-rostudirsen, faces regulatory and confirmatory risks, with FDA approval likely but long-term value now more uncertain due to functional outcome concerns.
Novartis AG Sponsored ADR (NOTA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Novartis AG Sponsored ADR ever had a stock split?
Novartis AG Sponsored ADR Profile
| Pharmaceuticals Industry | Healthcare Sector | Vasant Narasimhan CEO | XFRA Exchange | 66987V109 CUSIP |
| CH Country | 75,267 Employees | 11 Mar 2026 Last Dividend | 9 Apr 2019 Last Split | 18 Nov 1991 IPO Date |
Overview
Novartis AG is a globally recognized healthcare company based in Basel, Switzerland, with operations extending around the world. Since its incorporation in 1996, Novartis has been at the forefront of pharmaceutical research and development, dedicating efforts to producing medicines that address a wide spectrum of diseases and health conditions. The company's commitment to innovation and improving patient outcomes is demonstrated through its extensive portfolio of healthcare products, which are designed to meet the needs of patients and physicians across various therapeutic areas. Additionally, Novartis AG engages in significant partnerships and collaborations, such as with Alnylam Pharmaceuticals and Dawn Health, to enhance its product offerings and leverage technological advancements in medicine.
Products and Services
Novartis AG provides a diverse range of healthcare solutions, focusing on several key therapeutic areas. Each of these areas benefits from Novartis's commitment to research and development, producing medications and technologies that aim to improve the quality of life for patients worldwide:
- Cardiovascular, Renal and Metabolic: Novartis offers innovative treatments for managing heart diseases, kidney diseases, and metabolic disorders, helping patients manage symptoms and improve their health outcomes.
- Immunology: The company develops drugs that support the immune system, providing relief and treatment for autoimmune diseases and other conditions that affect the body's natural defense mechanisms.
- Neuroscience: Novartis's neuroscience portfolio addresses neurological and psychiatric disorders, aiming to restore brain health and improve the lives of those living with these conditions.
- Oncology: A leading area for Novartis, their oncology segment includes groundbreaking therapies for various types of cancer, contributing to the advancement of cancer treatment and care.
- Ophthalmology: Specializing in eye diseases, Novartis offers treatments that preserve vision and improve eye health, addressing some of the most common causes of vision loss.
- Hematology: Novartis provides therapies for blood disorders, focusing on treatments that can significantly impact the management of these diseases.
In addition to these pharmaceutical products, Novartis has forged partnerships to enhance its offerings:
- License and Collaboration with Alnylam Pharmaceuticals: This partnership focuses on the development, manufacture, and commercialization of inclisiran, a novel therapy aimed at reducing LDL cholesterol levels, which is a major risk factor for cardiovascular diseases.
- Partnership with Dawn Health: Through its collaboration with Dawn Health, Novartis is working on Ekiva, a digital solution designed to support individuals living with Paroxysmal Nocturnal Hemoglobinuria. This initiative reflects Novartis's commitment to integrating technology and medicine for better healthcare outcomes.
